BioLife Solutions reports Q2 EPS (33c), consensus (1c)

Reports Q2 revenue $25.4M, consensus $23.71M. CEO Roderick de Greef commented, “We delivered another strong quarter with cell processing revenue increasing 28% year-over-year and marking our seventh consecutive quarter of sequential growth. Performance was led by our biopreservation media franchise, where we saw continued strength across both direct and distributor channels. Notably, customers with approved commercial therapies again represented approximately 40% of total BPM revenue – underscoring the recurring nature of our product and the spec’d in consistency of our model. With our media embedded in 16 approved therapies and supporting more than 250 ongoing commercial trials, including over 30 in Phase III, we’ve established BioLife as the default partner for clinical programs across all phases, including later stage trials where clinical success is more likely and the path to commercial revenue is clearest. With this momentum and improved visibility into the second half, even against an uncertain macro backdrop, we are raising our full year guidance for cell processing revenue. Continued outperformance in cell processing and meaningful year-over-year expansion in adjusted EBITDA margin reflect the operating leverage and financial benefits of our streamlined operations and focused product portfolio – positioning BioLife to deliver sustained growth and long-term shareholder value.”